Search research articles
Contact Us
Filters
Showing results (81-90 of 118) with videos related to
Page
of 12
Sort By:
Oncology
|
November 29, 2008
Carboplatin and pegylated liposomal doxorubicin for advanced ovarian cancer: preliminary activity results of the MITO-2 phase III trial
S Pignata, G Scambia, A Savarese, et al.
British Journal of Cancer
|
May 9, 2007
A multicentre phase II study of carboplatin plus pegylated liposomal doxorubicin as first-line chemotherapy for patients with advanced or recurrent endometrial carcinoma: the END-1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) group
S Pignata, G Scambia, C Pisano, et al.
Current Medicinal Chemistry
|
January 2, 2013
Deregulation of HOX B13 expression in urinary bladder cancer progression
L Marra, M Cantile, G Scognamiglio, et al.
Current Cancer Drug Targets
|
April 3, 2012
High CXCR4 expression correlates with sunitinib poor response in metastatic renal cancer
C D' Alterio, L Portella, A Ottaiano, et al.
European Review for Medical and Pharmacological Sciences
|
July 30, 2013
Intravesical chemo-immunotherapy in non muscle invasive bladder cancer
D Leopardo, S C Cecere, M Di Napoli, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 3, 2019
ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease†
N Colombo, C Sessa, A du Bois, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 10, 1999
Phase II study of cisplatin and vinorelbine as first-line chemotherapy in patients with carcinoma of the uterine cervix
S Pignata, G Silvestro, E Ferrari, et al.
Oncology
|
May 27, 1999
A phase I study of paclitaxel and epirubicin, without and with filgrastim, for the treatment of platinum-resistant advanced ovarian cancer
R Lauria, E Ferrari, S Tramontana, et al.
ESMO Real World Data and Digital Oncology
|
February 6, 2026
Establishment of the Campania Oncology Network (Rete Oncologica Campana, ROC): a paradigm shift in oncological care and real world research in the Campania region
E Coppola, I De Santo, A Luongo, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
May 4, 2019
ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease
N Colombo, C Sessa, A du Bois, et al.
Page
of 12
Search research articles
Search
Showing results (81-90 of 118) with videos related to
Sort By:
Page
of 12
Oncology
|
November 29, 2008
Carboplatin and pegylated liposomal doxorubicin for advanced ovarian cancer: preliminary activity results of the MITO-2 phase III trial
S Pignata, G Scambia, A Savarese, et al.
British Journal of Cancer
|
May 9, 2007
A multicentre phase II study of carboplatin plus pegylated liposomal doxorubicin as first-line chemotherapy for patients with advanced or recurrent endometrial carcinoma: the END-1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) group
S Pignata, G Scambia, C Pisano, et al.
Current Medicinal Chemistry
|
January 2, 2013
Deregulation of HOX B13 expression in urinary bladder cancer progression
L Marra, M Cantile, G Scognamiglio, et al.
Current Cancer Drug Targets
|
April 3, 2012
High CXCR4 expression correlates with sunitinib poor response in metastatic renal cancer
C D' Alterio, L Portella, A Ottaiano, et al.
European Review for Medical and Pharmacological Sciences
|
July 30, 2013
Intravesical chemo-immunotherapy in non muscle invasive bladder cancer
D Leopardo, S C Cecere, M Di Napoli, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 3, 2019
ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease†
N Colombo, C Sessa, A du Bois, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 10, 1999
Phase II study of cisplatin and vinorelbine as first-line chemotherapy in patients with carcinoma of the uterine cervix
S Pignata, G Silvestro, E Ferrari, et al.
Oncology
|
May 27, 1999
A phase I study of paclitaxel and epirubicin, without and with filgrastim, for the treatment of platinum-resistant advanced ovarian cancer
R Lauria, E Ferrari, S Tramontana, et al.
ESMO Real World Data and Digital Oncology
|
February 6, 2026
Establishment of the Campania Oncology Network (Rete Oncologica Campana, ROC): a paradigm shift in oncological care and real world research in the Campania region
E Coppola, I De Santo, A Luongo, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
May 4, 2019
ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease
N Colombo, C Sessa, A du Bois, et al.
Page
of 12